The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Abstract
PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating hypercalcemia of malignancy (HCM). PATIENTS AND METHODS: Patients with moderate to severe HCM (corrected serum calcium [CSC] ≥ 3.00 mmol/L [12.0 mg/dL]) were treated with a single dose of zoledronic acid (4 or 8 mg) via 5-minute infusion or pamidronate (90 mg) via 2-hour infusion. A protocol-specified pooled analysis of the two parallel trials was performed. Clinical end points included rate of complete response by day 10, response duration, and time to relapse. RESULTS: Two hundred eighty-seven patients were randomized and evaluated for safety; 275 were evaluated for efficacy. Both doses of zoledronic acid were superior to pamidronate in the treatment of HCM. The complete response rates by day 10 were 88.4% (P = .002), 86.7% (P = .015), and 69.7% for zoledronic acid 4 mg and 8 mg and pamidronate 90 mg, respectively. Normalization of CSC occurred by day 4 in approximately 50% of patients treated with zoledronic acid and in only 33.3% of the pamidronate-treated patients. The median duration of complete response favored zoledronic acid 4 and 8 mg over pamidronate 90 mg with response durations of 32, 43, and 18 days, respectively. CONCLUSION: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Self-citationBerenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Self-citationMundy, G. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1546::aid-cncr4>3.0.co;2-i · Cited by 440
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
The Hypercalcemia of Cancer: Clinical Implications and Pathogenic Mechanisms
Mundy, G. R., Ibbotson, K. J., D'Souza, S. M., Simpson, E. L., Jacobs, J. W., & Martin, T. J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198406283102607 · Cited by 353
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J., & Lichtenstein, A. (1998) · Leukemia · doi:10.1038/sj.leu.2400892 · Cited by 259
Benford, H. L., Frith, J. C., Auriola, S., Mönkkönen, J., & Rogers, M. J. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26392-6 · Cited by 256
Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999) · Osteoporosis International · doi:10.1007/pl00004164 · Cited by 240
Nussbaum, S. R., Younger, J., Vandepol, C. J., Gagel, R. F., Zubler, M. A., Chapman, R., Henderson, I. C., & Mallette, L. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90282-t · Cited by 228
Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy
Zojer, N., Keck, A. V., & Pecherstorfer, M. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00004 · Cited by 167
A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients
Body, J. J., Lortholary, A. H., Romieu, G., Vigneron, A.-M., & Ford, J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1557 · Cited by 151
Self-citationGucalp, R. A., Ritch, P. S., Wiernik, P. H., Sarma, P. R., Keller, A. M., Richman, S. P., Tauer, K. W., Neidhart, J. A., Mallette, L. E., & Siegel, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.134 · Cited by 150
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E., Thurlimann, B. J. K., Walls, J., Lichinitser, M., Rizzoll, R., Hagberg, H., Huss, H., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.48 · Cited by 129
Self-citationBerenson, J. R., Vescio, R. A., Rosen, L. S., VonTeichert, J. M., Woo, M., Swift, R. A., Savage, A., Givant, E., Hupkes, M., Harvey, H. A., et al. (2001) · PubMed · Cited by 102
Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short‐Term Rat Models
Green, J. R., Seltenmeyer, Y., Jaeggi, K. A., & Widler, L. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb01964.x · Cited by 87
Body, J., Borkowski, A. J., Cleeren, A., & Bijvoet, O. L. M. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1177 · Cited by 74
Self-citationGucalp, R. A., Theriault, R., Gill, I., Madajewicz, S., Chapman, R., Navari, R., Ahmann, F., Zelenakas, K., Heffernan, M., & Knight, R. D. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420170079008 · Cited by 74
Thiébaud, D., Jaeger, P., Jacquet, A. F., & Burckhardt, P. (1986) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650010610 · Cited by 62
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
Nussbaum, S. R., Warrell, R. P., Rude, R. K., Glusman, J. E., Bilezikian, J. P., Stewart, A. F., Stepanavage, M., Sacco, J. F., Averbuch, S. D., & Gertz, B. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1618 · Cited by 54
Thiébaud, D., Jaeger, P., & Burckhardt, P. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050304 · Cited by 51
Body, J. J., Magritte, A., Seraj, F., Sculier, J., & Borkowski, A. J. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040617 · Cited by 48
Self-citationCantwell, B. M. J., & Harris, A. L. (1987) · BMJ · doi:10.1136/bmj.294.6570.467 · Cited by 43
Sawyer, N., Newstead, C. G., Drummond, A., & Cunningham, J. (1990) · Bone and Mineral · doi:10.1016/0169-6009(90)90078-t · Cited by 32
Disodium Pamidronate Versus Mithramycin in the Management of Tumour-Associated Hypercalcemia
Østenstad, B., & Andersen, O. K. (1992) · Acta Oncologica · doi:10.3109/02841869209089719 · Cited by 17
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Hypercalcemia Associated with Cancer
Stewart, A. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042806 · Cited by 973
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Self-citationRosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citation
Metadata
- Authors
- Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., & Seaman, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-15
- Volume
- 19
- Issue
- 2
- Pages
- 558-567
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1951349736
- Cited by
- 858
- References
- 25
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.